



NDA 020702/S-073

**SUPPLEMENT APPROVAL**

Pfizer Inc.  
U.S. Agent for Pfizer Ireland Pharmaceuticals, an Irish partnership  
Attention: Marcio de Godoy, MBA, PharmD, PhD  
Senior Manager, Worldwide Safety and Regulatory  
500 Arcola Rd, G4347  
Collegeville, PA 19426

Dear Dr. de Godoy:

Please refer to your Supplemental New Drug Application (sNDA) dated and received October 12, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lipitor (atorvastatin calcium) tablets; 10 mg, 20 mg, 40 mg, 80 mg.

This Prior Approval supplemental new drug application provides for revisions in the United States Package Insert (USPI) for Lipitor to update information regarding drug interactions between atorvastatin and certain protease inhibitors. In addition, subsection "Before You Start Lipitor" of the Patient Information, was updated to reflect hepatitis C virus in the list of medicines that patients should especially inform their doctors if they take the medicine.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Martin White, M.S., Regulatory Project Manager, at (240) 402-6018.

Sincerely,

*{See appended electronic signature page}*

William Chong, M.D.  
Deputy Director (Acting)  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling  
Prescribing Information  
Patient Package Insert

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

LISA B YANOFF  
04/12/2019 01:44:48 PM  
signing on behalf of Dr. Chong